Diabetes Prediction During Pregnancy and In Utero Using Pancreas MRI
Project Number1R01HD115565-01
Contact PI/Project LeaderVIROSTKO, JOHN MICHAEL
Awardee OrganizationUNIVERSITY OF TEXAS AT AUSTIN
Description
Abstract Text
PROJECT SUMMARY
The pancreas is smaller in individuals with diabetes and individuals at increased risk for developing diabetes,
suggesting that small pancreas size may convey risk for developing the disease. However, it is not known
whether individuals at risk for developing diabetes are born with a smaller pancreas or whether their pancreas
shrinks as part of the pathogenesis of the disease. Establishing the link between pancreas size and
development of diabetes is difficult, as the time course of diabetes progression is not well established and time
to progression can be long. However, pregnancy is a period of physiological beta cell proliferation that presents
a diabetogenic state with known and rapid onset. MRI can safely and noninvasively assay multiple aspects of
the maternal and fetal pancreas, including pancreas size as well as other markers of pancreas structure and
composition. Image acquisition and analysis will leverage our expertise assessing human pancreas size,
shape, fat content, and inflammation using multimodal quantitative MRI. We propose to perform longitudinal
MRI of the maternal pancreas over the course of pregnancy and postpartum and correlate imaging metrics with
diabetes development and metabolic phenotyping. We will also assess the capability of MRI to measure
pancreas growth in the fetus. Study participants will include mothers who not develop diabetes, mothers with
pregestational type 2 diabetes, and mothers who develop gestational diabetes during pregnancy. These
studies will establish the first model of maternal pancreas growth and multimodal imaging signature and their
interactions with diabetes. Our central hypothesis is that maternal pancreas growth will be altered by diabetes
and can be used to predict diabetes incidence in the mother. While the focus of this study is on the pancreas,
the images generated will encompass the maternal abdomen and entire fetus. Thus, the data generated will be
valuable datasets for secondary analysis of the interaction of diabetes with fetal development and maternal
liver, fat, and placenta dynamics over the course of pregnancy.
Public Health Relevance Statement
PROJECT NARRATIVE
This research examines the influence of pancreas dynamics during pregnancy on the development of diabetes.
MRI measurements of pancreas size, shape, and composition will be made over time in both the mother and
the fetus to see how the pancreas is affected by maternal diabetes. Pancreas phenotypes will be correlated
with metabolic phenotypes as assessed by glucose tolerance testing and continuous glucose monitoring.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AbdomenAffectBeta CellBiological AssayBirthCell PhysiologyCell ProliferationChildContinuous Glucose MonitorDataData SetDevelopmentDiabetes MellitusDiagnosisDiseaseDisease remissionEnergy MetabolismExhibitsFatty acid glycerol estersFetal DevelopmentFetusFunctional disorderGene ExpressionGestational DiabetesGlucose tolerance testGrowthHigh Risk WomanHormonalHormonesHumanImageIncidenceIndividualInfiltrationInflammationInsulin ResistanceLinkLiverMagnetic Resonance ImagingMeasurementMeasuresMetabolicMetabolismMethodsModelingMonitorMothersMultimodal ImagingNon-Insulin-Dependent Diabetes MellitusNuclearObesityOrganPancreasParticipantPathogenesisPhenotypePhysiologicalPlacentaPlayPostpartum PeriodPrediabetes syndromePregnancyProcessProliferatingResearchRiskRoleShapesStructureStructure of beta Cell of isletTestingTimeWeight GainWomanWomen's cohortWorkcellular imagingdiabetes riskdiabetogenicfetalglucose metabolismhigh riskimprovedin uteroinsulin secretionlifetime riskmaternal diabetesmetabolic phenotypemultimodalitynon-diabeticoffspringpancreas imagingsecondary analysistype I and type II diabetes
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
170230239
UEI
V6AFQPN18437
Project Start Date
01-September-2024
Project End Date
31-May-2029
Budget Start Date
01-September-2024
Budget End Date
31-May-2025
Project Funding Information for 2024
Total Funding
$613,253
Direct Costs
$389,749
Indirect Costs
$223,504
Year
Funding IC
FY Total Cost by IC
2024
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$613,253
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01HD115565-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01HD115565-01
Patents
No Patents information available for 1R01HD115565-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01HD115565-01
Clinical Studies
No Clinical Studies information available for 1R01HD115565-01
News and More
Related News Releases
No news release information available for 1R01HD115565-01
History
No Historical information available for 1R01HD115565-01
Similar Projects
No Similar Projects information available for 1R01HD115565-01